Response to Britz (2022) regarding the validity of the giant sunfish Mola alexandrini (Ranzani, 1834) (Teleostei: Molidae).

The small family of ocean sunfishes has a long and complicated taxonomic and nomenclatorial history dating back several centuries. Most recently, Britz (2022) questioned the validity of Mola alexandrini (Ranzani, 1839) as the valid name for Mola sp. A sensu Yoshita et al.

Indoor and outdoor human behavior and myopia: an objective and dynamic study.

Significance: Myopia holds significant public health concern given its social, ocular disease and economic burdens. Although environmental factors are primarily to blame for the rapid rise in prevalence, key risk factors remain unresolved.

Purpose: The aim of this study was to objectively characterize, using a wearable technology, the temporal indoor and outdoor behavioral patterns and associated environmental lighting characteristics of young myopic and nonmyopic University students.

A review of giants: Examining the species identities of the world's heaviest extant bony fishes (ocean sunfishes, family Molidae).

The world's heaviest extant bony fish has long been considered the ocean sunfish Mola mola (family Molidae). However, recent taxonomic research suggests the world record specimen (2300 kg) was actually a misidentified giant sunfish M. alexandrini.

Imatinib Mesylate Exerted Antitumor Effect by Promoting Infiltration of Effector T Cells in Tumor.

Imatinib mesylate is a potent tyrosine kinase inhibitor that may induce immunological effects, such as inhibition of immune suppressive cells; but, how it modulates the immune system remains to be completely elucidated. In this study, we showed that cell proliferation of CT26 colon cancer and Lewis lung carcinoma (3LL) lung cancer cells was not inhibited by imatinib in vitro, although its administration significantly suppressed the growth of CT26, but not 3LL, subcutaneous tumors, and prolonged survival in CT26 tumor-bearing mice. Further, we examined the expression of immune cell-related molecules in the tumors to elucidate the differences in imatinib-mediated antitumor effects between CT26 and 3LL tumors.